Iterum Therapeutics

Iterum Therapeutics(ITRM)

DUBLIN 1, Ireland
Biotechnology
WebsiteLinkedInCareers Page

Focus: Anti-infectives

Iterum Therapeutics is a life sciences company focused on Anti-infectives.

Infectious Diseases
Funding Stage
PUBLIC
Employees
5000+
Open Jobs
0

Products & Portfolio (1)

ORLYNVAH
sulopenem etzadroxil and probenecid
Growth
ORAL ยท TABLET
etzadroxil, a penem antibacterial drug [see Microbiology ] and probenecid, a renal tubular transport inhibitor. Probenecid inhibits OAT3-mediated renal clearance of sulopenem, resulting in increased plasma concentrations of sulopenem .
uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coliKlebsiella pneumoniaeProteus mirabilis in adult women+1 more
2024
0

Pipeline & Clinical Trials

Sulopenem Etzadroxil/Probenecid
Complicated Urinary Tract Infection
N/A
Clinical Trials (1)
NCT04682834Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
N/A
sulopenem etzadroxil and probenecid
Pharmacokinetics After Oral Intake
Phase 1
Clinical Trials (1)
NCT07092813Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
Phase 1
Phase 1
Clinical Trials (1)
NCT04700787Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
Phase 1
Sulopenem etzadroxil/probenecid
Urinary Tract Infections
Phase 3
Clinical Trials (1)
NCT05584657Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
Phase 3
Phase 3
Clinical Trials (1)
NCT03358576Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
Phase 3
Azithromycin plus hydroxychloroquine
Respiratory Tract Infection Viral
Phase 3
Clinical Trials (1)
NCT05026801Azithromycin Plus Hydroxychloroquine for COVID-19 Infection
Phase 3
Phase 3
Clinical Trials (1)
NCT03357614Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
Phase 3
Sulopenem-Etzadroxil/Probenecid
Uncomplicated Urinary Tract Infections
Phase 3
Clinical Trials (1)
NCT03354598Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
Phase 3
Phase 4
Clinical Trials (1)
NCT03366207Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 1 approved product, 9 clinical trials
Top TAs: Infectious Diseases
SEC Filings: 2 available
Portfolio Health
Growth1 (100%)
1 total products
Therapeutic Area Focus
Marketed
Pipeline

Financials (FY2024)

R&D Spend
$18M64%
Net Income
-$44M
Cash
$6M
Source: SEC 10-K Filing